This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Department of Psychiatry, University of British Columbia, Vancouver, Canada
  2. Drs Phaterpekar and Nunez contributed equally to this work.
  3. Department of Psychiatry, University of British Columbia, Vancouver, Canada
  4. Drs Phaterpekar and Nunez contributed equally to this work.
  5. Department of Psychiatry, University of British Columbia, Vancouver, Canada
  6. Department of Psychiatry, University of Alberta, Edmonton, Canada
  7. Department of Psychiatry, University of Alberta, Edmonton, Canada
  8. Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada
  9. Departments of Psychiatry and Psychology, Queen’s University, Kingston, Canada
  10. Department of Psychiatry, University of Toronto, Toronto, Canada
  11. Centre for Addiction and Mental Health, Toronto, Canada
  12. Department of Psychiatry, University of Toronto, Toronto, Canada
  13. Departments of Psychiatry and Psychology, Queen’s University, Kingston, Canada
  14. Department of Psychiatry, University of Calgary, Calgary, Canada
  15. Department of Psychiatry, Dalhousie University, Halifax, Canada
  16. Department of Psychiatry, University of Toronto, Toronto, Canada
  17. Department of Psychiatry, University of British Columbia, Vancouver, Canada
  1. Herrman H, Kieling C, McGorry P, et al. Reducing the global burden of depression: a Lancet-World Psychiatric Association Commission. Lancet. 2019;393(10189):e42–e43. PubMed CrossRef
  2. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. PubMed CrossRef
  3. Brenes GA. Anxiety, depression, and quality of life in primary care patients. Prim Care Companion J Clin Psychiatry. 2007;9(6):437–443. PubMed CrossRef
  4. Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry. 1999;56(10):897–904. PubMed CrossRef
  5. IsHak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J Affect Disord. 2013;151(1):59–65. PubMed CrossRef
  6. Schechter D, Endicott J, Nee J. Quality of life of ‘normal’ controls: association with lifetime history of mental illness. Psychiatry Res. 2007;152(1):45–54. PubMed CrossRef
  7. Morton E, Bhat V, Giacobbe P, et al; CAN-BIND Investigator Team. Impacts on quality of life with escitalopram monotherapy and aripiprazole augmentation in patients with major depressive disorder: A CAN-BIND report. Pharmacopsychiatry. 2021;54(5):225–231. PubMed CrossRef
  8. Morton E, Michalak EE, Levitt A, et al. Quality of life impacts of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized clinical trial. Can J Psychiatry. 2021;66(3):289–297. PubMed CrossRef
  9. Solomon DA, Leon AC, Endicott J, et al. Psychosocial impairment and recurrence of major depression. Compr Psychiatry. 2004;45(6):423–430. PubMed CrossRef
  10. IsHak WW, Greenberg JM, Balayan K, et al. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry. 2011;19(5):229–239. PubMed CrossRef
  11. Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals (Basel). 2010;3(1):19–41. PubMed CrossRef
  12. Ermers NJ, Hagoort K, Scheepers FE. The predictive validity of machine learning models in the classification and treatment of major depressive disorder: state of the art and future directions. Front Psychiatry. 2020;11:472. PubMed CrossRef
  13. Sajjadian M, Lam RW, Milev R, et al. Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. Psychol Med. 2021;51(16):2742–2751. PubMed CrossRef
  14. Cabitza F, Campagner A, Soares F, et al. The importance of being external. methodological insights for the external validation of machine learning models in medicine. Comput Methods Programs Biomed. 2021;208:106288. PubMed CrossRef
  15. Rush AJ, Fava M, Wisniewski SR, et al; STAR*D Investigators Group. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119–142. PubMed CrossRef
  16. Kennedy SH, Lam RW, Rotzinger S, et al; CAN-BIND Investigator Team. Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: A CAN-BIND-1 report. J Clin Psychiatry. 2019;80(2):18m12202. PubMed CrossRef
  17. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
  18. Lam RW, Milev R, Rotzinger S, et al; CAN-BIND Investigator Team. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry. 2016;16(1):105. PubMed CrossRef
  19. Battle DE. Diagnostic and Statistical Manual of Mental Disorders (DSM). CoDAS. 2013;25(2):191–192. PubMed
  20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
  21. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–326. PubMed
  22. IsHak WW, Mirocha J, James D, et al. Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up. Acta Psychiatr Scand. 2015;131(1):51–60. PubMed CrossRef
  23. Fayers PM, Machin D. Quality of Life: The Assessment, Analysis and Interpretation of Patient-Reported Outcomes. John Wiley & Sons; 2013.
  24. IsHak WW, Mirocha J, Pi S, et al. Patient-reported outcomes before and after treatment of major depressive disorder. Dialogues Clin Neurosci. 2014;16(2):171–183. PubMed CrossRef
  25. Nunez JJ, Nguyen TT, Zhou Y, et al. Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. PLoS One. 2021;16(6):e0253023. PubMed CrossRef
  26. Harris CR, Millman KJ, van der Walt SJ, et al. Array programming with NumPy. Nature. 2020;585(7825):357–362. PubMed CrossRef
  27. McKinney W. pandas: a foundational Python library for data analysis and statistics. Python High Performance Science Computer. 2011;14(9):1-9.
  28. Nie Z, Vairavan S, Narayan VA, et al. Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study. PLoS One. 2018;13(6):e0197268. PubMed CrossRef
  29. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: machine learning in python. J Machine Learn Res. 2011;12:2825–2830.
  30. Chekroud AM, Zotti RJ, Shehzad Z, et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry. 2016;3(3):243–250. PubMed CrossRef
  31. Kautzky A, Baldinger-Melich P, Kranz GS, et al. A new prediction model for evaluating treatment-resistant depression. J Clin Psychiatry. 2017;78(2):215–222. PubMed CrossRef
  32. Lundberg SM, Lee SI. A Unified Approach to Interpreting Model Predictions. In: Advances in Neural Information Processing Systems. Vol 30. Curran Associates, Inc; 2017.
  33. IsHak WW, Steiner AJ, Klimowicz A, et al. Major depression comorbid with medical conditions: analysis of quality of life, functioning, and depressive symptom severity. Psychopharmacol Bull. 2018;48(1):8–25. PubMed
  34. Bzdok D, Altman N, Krzywinski M. Statistics versus machine learning. Nat Methods. 2018;15(4):233–234. PubMed CrossRef
  35. McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29(3):243–259. PubMed CrossRef
  36. Cava W, Bauer C, Moore JH, et al. Interpretation of machine learning predictions for patient outcomes in electronic health records. AMIA Annu Symp Proc. 2020;2019:572–581. PubMed
  37. Tonekaboni S, Joshi S, McCradden MD, et al. What Clinicians Want: Contextualizing Explainable Machine Learning for Clinical End Use. In: Proceedings of the 4th Machine Learning for Healthcare Conference. PMLR; 2019:359-380.
  38. Kudlow PA, McIntyre RS, Lam RW. Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs. 2014;28(7):601–609. PubMed CrossRef
  39. Wagner S, Engel A, Engelmann J, et al. Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with major depressive disorder: systematic review and meta-analysis. J Psychiatr Res. 2017;94:96–106. PubMed CrossRef
  40. Morton E, Bhat V, Giacobbe P, et al; CAN-BIND Investigator Team. Predictors of quality of life improvement with escitalopram and adjunctive aripiprazole in patients with major depressive disorder: A CAN-BIND study report. CNS Drugs. 2021;35(4):439–450. PubMed CrossRef